Novoset, LLC and Lonza Announce the Introduction of New, Ultra-Low Dielectric Loss and High Temperature Materials for High-Speed Telecommunication Industries and Bendable Electronic Devices
The processing of these materials is similar to epoxy resins and other commercial PrimasetTM materials. The products co-react with epoxy resins, Polyphenylenether (PPE), Styrene maleic anhydride (SMA), Triallyl cyanurate (TAC), Bismaleinimide (BMI), Vinyl polymers, Primaset™ BA-230S, Primaset™ BA-3000, and other Cyanate esters. The products are soluble in Methyl ethyl ketone (MEK), Toluene, Xylenes and other solvents at high concentration. These products also give excellent adhesive characteristics with various substrates and can be highly filled with fillers for low CTE applications. Dr. Sajal Das, President & CEO of Novoset, LLC stated: "We can design and fabricate high-layer count ultra-low dielectric boards without using Teflon™. PrimasetTM ULL-950's electrical performance is similar to Polytetrafluoroethylene, it can be processed as easy as FR-4 technology and reaches Tg of Cyanate esters or Polyimides". He further commented that: "We are getting close to fabricating bendable tablets, smartphones and other devices from high temperature thermosets such as derivatives of PrimasetTM ULL-950 and PrimasetTM HTL-300 in the foreseeable future."
ULL-950 and HTL-300 were developed at Novoset Technology Center, in Berkeley Heights, NJ. Lonza will manufacture and market these two products globally under Primaset™ trade name.
About Novoset, LLC
Novoset, LLC was established in 2011 as a product design, development and marketing company specializing in high performance thermoset plastics and formulated intermediate products for the electronics, aerospace, space and defense industries. Novoset, LLC has opened its Technology Center in October 2012. Lonza is Novoset's manufacturing partner.
Novoset, LLC is located in Peapack, New Jersey, USA. Further information can be found at
Lonza Group Ltd.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of ingredients to the nutrition and agro markets world and a leading producer of thermoset resins and various advanced intermediates with backward integrated feedstock capabilities.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2012, the company had sales of CHF 3'925 million. Further information can be found at www.lonza.com.